Alex A. Cruz

  • Citations Per Year
Learn More
BACKGROUND Squamous cell carcinoma and adenocarcinoma account for more than 90% of all esophageal cancer cases. Although the incidence of squamous cell carcinoma has declined, the incidence of adenocarcinoma has risen due to increases in obesity and gastroesophageal reflux disease. METHODS The authors examine the role of radiation therapy alone (external(More)
PURPOSE To assess outcomes with external beam radiation therapy (EBRT) and a low-dose-rate (LDR) brachytherapy boost without or with androgen deprivation therapy (ADT) for prostate cancer. MATERIALS AND METHODS From January 2001 through August 2011, 120 intermediate-risk or high-risk prostate cancer patients were treated with EBRT to a total dose of 4,500(More)
PURPOSE To compare urinary, bowel, and sexual health-related quality-of-life (HRQOL) changes due to high-dose-rate (HDR) brachytherapy, low-dose-rate (LDR) brachytherapy, or intensity-modulated radiation therapy (IMRT) monotherapy for prostate cancer. METHODS AND MATERIALS Between January 2002 and September 2013, 413 low-risk or favorable(More)
9 Background: PET-CT is an important tool for staging and evaluating treatment response in esophageal cancer. Metabolic tumor volume (MTV) has been reported as a prognostic factor in other malignancies. We evaluated the utility of post-radiation MTV in esophageal cancer patients treated with chemoradiotherapy (CRT). METHODS We evaluated pre- and(More)
The objectives are to determine predictors of a prostate-specific antigen (PSA) bounce, whether a PSA bounce after radiotherapy for prostate cancer is associated with biochemical disease-free survival (bDFS), and the time course to a PSA bounce versus a biochemical failure post-irradiation. Between July 2000 and December 2012, 691 prostate cancer patients(More)
  • 1